Today: 9 June 2026
London Stock Exchange Group share price slides again as AI fears keep hitting LSEG stock

London Stock Exchange Group share price slides again as AI fears keep hitting LSEG stock

London, Feb 4, 2026, 10:45 GMT — Regular session

Shares of London Stock Exchange Group plc (LSEG.L) slipped roughly 1.8% to 7,048 pence by 10:39 GMT, after dipping as low as 6,684 pence earlier. That kept the stock close to a new 52-week low.

The decline stretched a two-day selloff in software and data stocks, sparked by Anthropic’s latest moves that revived fears faster AI tools could erode subscription revenue and future growth estimates. JP Morgan’s Toby Ogg noted investors seem to be “sentenced before trial,” with little enthusiasm to buy the dip. Reuters

Worries have spilled over from just software. Investors fear “AI agents” — tools capable of handling instructions and managing tasks across multiple apps — will improve quickly and force a rethink on the value of data, workflows, and compliance products.

“Anthropic is now, quite clearly, parking its tanks on their lawn,” said IG chief markets strategist Chris Beauchamp, summing up the mounting pressure on sector business models. The European Central Bank and Bank of England both hold meetings Thursday, setting the stage to challenge risk appetite following the sudden repricing. Reuters

Anthropic rolled out plug-ins for its Claude Cowork agent on Friday, aiming to automate jobs in legal, sales, marketing, and data analysis, Reuters reported. “Sometimes the market just shoots first and asks questions later,” said Mike Archibald, a portfolio manager at AGF Investments, as shares in companies linked to legal and data workflows took a steep hit. Reuters

LSEG revealed it purchased 253,226 ordinary shares on Feb. 3 under its buyback plan, at an average price of 7,685.36 pence each, with the intention to cancel them. Following this, the company will have 507,012,183 voting shares outstanding, not counting treasury stock.

LSEG operates across financial markets infrastructure and data services, covering Data & Analytics, the FTSE Russell index business, Risk Intelligence, Capital Markets, and Post Trade services, per a Reuters company profile. This broad offering means traders often group it with workflow and analytics companies when sentiment shifts against “software” exposure. Reuters

On Tuesday, LSEG tumbled 12.7% amid a broader AI-driven selloff that pushed the UK technology index down 11.8%. The FTSE 100 slipped 0.26%, Reuters reported. “Risk appetite just isn’t fully restored,” noted Swissquote Bank analyst Ipek Ozkardeskaya, as investors brace for Thursday’s Bank of England decision. Reuters

LSEG holders now face a key question: is this just a sudden jolt sparked by new product news, or the beginning of a gradual decline as investors rethink their long-term bets? The sharp swings over two sessions cloud the real price signal; liquidity appears briefly, then vanishes.

The decline might deepen if additional AI tools target revenue-generating data and professional workflows, or if companies opt to develop in-house solutions rather than renew contracts. Another round of sessions like this could push the selloff beyond a sector hiccup, turning it into a wider de-rating.

Traders will be on the lookout for whether the sell-off spreads to other UK defensives or remains focused on stocks linked to data, compliance, and workflow products. If bargain hunters return, expect them to pick their spots rather than dive in all at once.

LSEG is set to release its preliminary results for the year ended Dec. 31, 2025, on Feb. 26, per its investor relations calendar.

Stock Market Today

  • Designer Brands (DBI) Beats Q1 Earnings and Revenue Estimates
    June 9, 2026, 10:04 AM EDT. Designer Brands (DBI) reported Q1 earnings of $0.07 per share, surpassing the Zacks estimate of $0.02 and reversing a year-ago loss of $0.26. Revenue hit $696.35 million, just above the $696 million consensus. The company delivered a 250% earnings surprise and has beaten EPS estimates in four consecutive quarters. Shares rose about 19.5% year-to-date, outpacing the S&P 500's 8.2% gain. Despite strong results, the stock holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market. The Retail - Apparel and Shoes sector ranks among the top three industries. Future stock performance will depend on management's outlook and upcoming earnings estimate revisions, with current consensus estimates at $0.30 EPS on $744 million revenue next quarter and $0.35 EPS on $2.91 billion revenue for the fiscal year.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Take-Two (TTWO) stock eyes a sharp open after forecast raise, GTA VI date held
Previous Story

Take-Two (TTWO) stock eyes a sharp open after forecast raise, GTA VI date held

Apple stock jumps as Goldman flags App Store spending pickup, keeping AAPL in focus
Next Story

Apple stock jumps as Goldman flags App Store spending pickup, keeping AAPL in focus

Go toTop